Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24588805 | 0.86 | EPHX2 (0.43) | LPAR2LPAR3LPAR1ALDH1A1CNR1 | |
| SCHEMBL24587960 | 0.86 | EPHX2 (0.43) | LPAR2LPAR3LPAR1ALDH1A1CNR1 | |
| SCHEMBL24573108 | 0.85 | ALDH1A1 (0.37) | LPAR2LPAR3LPAR1ALDH1A1CNR1 | |
| SCHEMBL26731555 | 0.83 | ALDH1A1 (0.42) | ALDH1A1TP53ALOX15KDM4ELMNA | |
| SCHEMBL21828359 | 0.83 | ALDH1A1 (0.42) | ALDH1A1TP53ALOX15KDM4ELMNA | |
| SCHEMBL21828343 | 0.83 | ALDH1A1 (0.42) | ALDH1A1TP53ALOX15KDM4ELMNA | |
| SCHEMBL24587987 | 0.82 | ALDH1A1 (0.45) | LPAR2LPAR3LPAR1ALDH1A1CNR1 | |
| SCHEMBL24587947 | 0.82 | EPHX2 (0.44) | ALDH1A1CNR1CNR2ALOX15HSD17B10 | |
| SCHEMBL24588573 | 0.81 | EPHX2 (0.43) | LPAR2LPAR3LPAR1ALDH1A1CNR1 | |
| SCHEMBL24588727 | 0.80 | ALDH1A1 (0.45) | LPAR2LPAR3LPAR1ALDH1A1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262817-A1 | NANOMATERIALS COMPRISING ACETALS | Beam Therapeutics Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230331656-A1 | NANOMATERIALS COMPRISING ACETALS | BEAM THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331656-A1 | NANOMATERIALS COMPRISING ACETALS | BEAM THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| CN-116782913-A | Nanomaterials comprising acetals | 比姆医疗股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2022140238-A1 | NANOMATERIALS COMPRISING ACETALS | BEAM THERAPEUTICS INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140238-A1 | NANOMATERIALS COMPRISING ACETALS | BEAM THERAPEUTICS INC. (US) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331656-A1 | NANOMATERIALS COMPRISING ACETALS | SGMS1, SGMS2, LIPA | LPAR2 833/4885LPAR3 637/4885LPAR1 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.